Alchemia wins patents for generic fondaparinux

The Australian patent and divisional patent were recently sealed by IP Australia. A further two divisional applications have completed the examination process and have been accepted to grant. Both of these are expected to be sealed in the next few months. These patents are currently being examined in other major markets.

Alchemia and its manufacturing partner Dr Reddy’s have made progress towards commercialization of fondaparinux, with approval and launch expected in the first half of 2009, depending on review time at the FDA.

Michael West, vice president of intellectual property for Alchemia, said: “This patent family provides legal protection for Alchemia’s processes for the synthesis of fondaparinux sodium through to September 6, 2022. These patents and the corresponding applications in other jurisdictions provide a good framework to protect our industrial synthesis of fondaparinux.”